New drug combo aims to prevent transplant complications in older leukemia patients
NCT ID NCT06973668
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This study compares two drug combinations to prevent graft-versus-host disease (GVHD) after a stem cell transplant in people aged 65 and older with acute myeloid leukemia or related blood cancers. Participants will receive either cyclophosphamide, sirolimus, and mycophenolate mofetil or cyclophosphamide, sirolimus, and ruxolitinib. The goal is to see which combination is safer and more effective at preventing GVHD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.